Exact Mass: 260.19874880000003
Exact Mass Matches: 260.19874880000003
Found 57 metabolites which its exact mass value is equals to given mass value 260.19874880000003,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ropinirole
C16H24N2O (260.18885339999997)
Ropinirole is a non-ergoline dopamine agonist, manufactured by GlaxoSmithKline. It is used in the treatment of Parkinsons disease, and is also one of two medications in the United States with an FDA-approved indication for the treatment of restless legs syndrome (the other being Pramipexole). [Wikipedia] D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
Oxymetazoline
C16H24N2O (260.18885339999997)
Oxymetazoline is only found in individuals that have used or taken this drug. It is a direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion. R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AB - Sympathomimetics, combinations excl. corticosteroids R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AA - Sympathomimetics, plain S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics > S01GA - Sympathomimetics used as decongestants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D019141 - Respiratory System Agents > D014663 - Nasal Decongestants D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents D - Dermatologicals
3-(2-(Diisopropylamino)ethyl)-1H-indol-5-OL
C16H24N2O (260.18885339999997)
5-Methoxy-N-ethyl-n-propyltryptamine
C16H24N2O (260.18885339999997)
N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide
C16H24N2O (260.18885339999997)
N-Demethyl-α-obscurine
C16H24N2O (260.18885339999997)
ropinirole
C16H24N2O (260.18885339999997)
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent CONFIDENCE standard compound; INTERNAL_ID 2711
2-(4-(TERT-BUTYL)PHENYL)-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE
4-BENZYL-2-((PYRROLIDIN-1-YL)METHYL) MORPHOLINE
C16H24N2O (260.18885339999997)
4-(1-benzyl-piperidin-4-yl)-morpholine
C16H24N2O (260.18885339999997)
4,4,5,5-tetramethyl-2-(4-phenylbutyl)-1,3,2-dioxaborolane
2-(4-Isobutylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
N-(1-benzylpiperidin-4-yl)-2-methylpropanamide
C16H24N2O (260.18885339999997)
4-Hydroxy-N,N-diisopropyltryptamine
C16H24N2O (260.18885339999997)
DODECYLMETHYLSILOXANE, 2-PHENYLPROPYLMETHYLSILOXANE COPOLYMER
4,4,5,5-tetramethyl-2-(2-methyl-6-propan-2-ylphenyl)-1,3,2-dioxaborolane
n-Cyclohexyl-n-(propyl)phenyl urea
C16H24N2O (260.18885339999997)
1-[4-(2,3-Dimethylphenyl)-1-piperazinyl]-2-methyl-1-propanone
C16H24N2O (260.18885339999997)
(3R)-3,14-dihydroxymyristic acid
A dihydroxy monocarboxylic acid that is 17-hydroxymyristic acid in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group.
(3R,13R)-3,13-dihydroxymyristic acid
An (omega-1)-hydroxy fatty acid that is (13R)-13-hydroxymyristic acid in which the 3-pro-R hydrogen is replaced by a hydroxy group.
oxymetazoline
C16H24N2O (260.18885339999997)
R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AB - Sympathomimetics, combinations excl. corticosteroids R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AA - Sympathomimetics, plain S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics > S01GA - Sympathomimetics used as decongestants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D019141 - Respiratory System Agents > D014663 - Nasal Decongestants D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents D - Dermatologicals
(1s,9r,10s,16s)-16-methyl-6,14-diazatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),5-dien-5-ol
C16H24N2O (260.18885339999997)
(1r,9s,10r,16s)-16-methyl-6,14-diazatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),5-dien-5-ol
C16H24N2O (260.18885339999997)
(1s,7s,9s,11s)-11-methyl-2,17-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-13-en-3-one
C16H24N2O (260.18885339999997)
16-methyl-6,14-diazatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),5-dien-5-ol
C16H24N2O (260.18885339999997)